重组人白细胞介素1受体拮抗蛋白荧光质粒在软骨细胞的表达

背景：白细胞介素1受体拮抗蛋白能延缓骨性关节炎进程,通过转基因方法可以使白细胞介素1受体拮抗蛋白表达的增加。 目的：观察重组人重组人白细胞介素1受体拮抗蛋白荧光质粒的构建及经脂质体转染软骨细胞的表达情况。 方法：双酶切法切取重组人白细胞介素1受体拮抗蛋白的c-DNA片段,通过T4DNA连接酶连接到pEGFP-C1载体上。体外分离培养兔关节软骨细胞,然后用构建的重组人白细胞介素1受体拮抗蛋白质粒经脂质体转染软骨细胞,通过荧光显微镜观察转基因的表达和荧光定量PCR检测其表达。 结果与结论：获得重组人pEGFP-C1-IL-1Ra真核表达载体质粒,酶切及测序结果证明表达质粒的DNA序列完全正确。荧光显微镜观察有绿色荧光蛋白表达,荧光定量PCR鉴定证实转染的软骨细胞基因得到表达。     

慢性乙型肝炎患者白细胞介素-1受体拮抗剂IL-1ra基因多态性

目的探讨白细胞介素-1受体拮抗剂内含子2可变串联重复序列基因多态性与慢性乙型肝炎相关性.方法利用聚合酶链式反应技术对56例慢性乙型肝炎及100例正常对照者的白细胞介素-1受体拮抗剂基因进行扩增.结果慢性乙型肝炎患者IL-1ra基因频率:IL1RN1/1 0.8214,IL1RN1/2 0.1607,IL1RN1/4 0.0179,IL-1ra等位基因频率:IL1RN*1 0.9107,IL1RN*2 0.0804,IL1RN*4 0.0089,与正常对照组无明显差异(p>0.05).结论慢性乙型肝炎患者IL-1ra基因多态性的分布与正常人无明显差异.     

慢性乙型肝炎患者白细胞介素-1受体拮抗剂IL-1ra基因多态性

目的 探讨白细胞介素-1受体拮抗剂内含子2可变串联重复序列基因多态性与慢性乙型肝炎相关性．方法 利用聚合酶链式反应技术对56例慢性乙型肝炎及100例正常对照者的白细胞介素-1受体拮抗剂基因进行扩增．结果 慢性乙型肝炎患者IL-1ra基因频率：IL1RN1／10．8214，IL1RN1／20．1607，IL1RN1／40．0179，IL-1ra等位基因频率：IL1RN ＊ 10．9107，IL1RN ＊ 20．0804，IL1RN ＊ 40．0089，与正常对照组无明显差异（p〉0．05）．结论 慢性乙型肝炎患者IL-1ra基因多态性的分布与正常人无明显差异．     

广东汉族人儿童白细胞介素-1受体拮抗剂基因多态性

目的了解广东汉族人白细胞介素-1受体拮抗剂基因的分布特点.方法应用聚合酶链反应技术对156例正常人白细胞介素-1受体拮抗剂基因进行扩增并进行图谱分析.并进行了不同种族间的分析比较.结果广东汉族人群中IL-1ra基因表型频率:IL1RN1/1 0.8205,IL1RN1/2 0.1731,IL1RN1/3 0.0064,IL-1ra等位基因频率:IL1RN*1 0.9103,IL1RN*2 0.0865,IL1RN*3 0.0032.结论白细胞介素-1受体拮抗剂基因多态性在不同种族间分布存在着明显的差异.     

广东汉族人儿童白细胞介素-1受体拮抗剂基因多态性

目的 了解广东汉族人白细胞介素-l受体拮抗剂基因的分布特点．方法 应用聚合酶链反应技术对156例正常人白细胞介素-l受体拮抗剂基因进行扩增并进行图谱分析．并进行了不同种族间的分析比较．结果 广东汉族人群中IL-1ra基因表型频率：ILlRN1／l0．8205，ILlRN1/20．173l，ILlRN1／30．0064，IL-lra等位基因频率：ILlRN*l0．9103，ILlRN*20．0865，ILlRN*30．0032．结论 白细胞介素-l受体拮抗剂基因多态性在不同种族间分布存在着明显的差异．     

用包涵体复性的方法制备重组人白细胞介素-1受体拮抗剂

通过大肠杆菌将IL-1ra表达成包涵体,将包涵体用8M尿素溶解后,稀释4倍后直接用离子交换柱层析进行复性和纯化,复性后得到的IL-1ra纯度大于95%,生物活性大于1×105IU/mg,内毒素含量也比较低。Western-Blotting印迹也表明重组蛋白具有IL-1ra的抗原活性。     

白细胞介素-1受体拮抗剂基因多态性与变态性鼻炎相关性探讨

目的　探讨白细胞介素 - 1受体拮抗剂 (IL -lra)基因多态性与变态性鼻炎相关性 .方法　利用聚合酶链式反应技术对 6 9例变态性鼻炎患者及 15 6例正常对照者的IL -lra基因进行扩增 .结果　变态性鼻炎患者IL - 1ra基因频率 :IL1RN1/ 10 .8116 ,IL1RN1/ 2 0 .1739,IL1RN1/ 30 .0 14 5 ,IL - 1ra等位基因频率 :,IL1RN 10 .90 5 8,IL1RN 20 .0 86 9,IL1RN 30 .0 0 72 ,与对照组无差异 (p >0 .0 5 ) .结论　IL - 1ra基因多态性的分布与变态性鼻炎无明显相关性     

白细胞介素-1受体拮抗剂基因多态性与变态性鼻炎相关性探讨

目的探讨白细胞介素-1受体拮抗剂(IL-lra)基因多态性与变态性鼻炎相关性.方法利用聚合酶链式反应技术对69例变态性鼻炎患者及156例正常对照者的IL-lra基因进行扩增.结果变态性鼻炎患者IL-1ra基因频率:IL1RN1/1 0.8116,IL1RN1/2 0.1739,IL1RN1/3 0.0145,IL-1ra等位基因频率:,IL1RN*1 0.9058,IL1RN*2 0.0869,IL1RN*3 0.0072,与对照组无差异(p>0.05).结论 IL-1ra基因多态性的分布与变态性鼻炎无明显相关性.     

糖尿病肾病患者血清可溶性白细胞介素6受体检测

糖尿病肾病 (ＤＮ )的发病机制尚不明确 ,有报道ＩＬ 6可引起肾小球系膜及血管平滑肌细胞增生 ,而ＩＬ 6发挥作用须先与其血清中的ｓＩＬ 6Ｒ结合[1,2 ] 。本文通过检测ＤＮ患者血清ｓＩＬ 6Ｒ水平 ,探讨其临床价值。1　对象和方法1 1　对象　健康志愿者 30例作为对照组 ,临床确诊的糖尿病患者 91例 ,1型 (Ａ组 ) 2 9例 ,2型 (Ｂ组 ) 6 2例 ,无高血压、心脑血管疾病及其它肾脏疾病 ,尿白蛋白排泄率(ＵＡＥＲ )为 2 0 μｇ/ｍｉｎ～ 2 0 0 μｇ/ｍｉｎ。常规检测空腹及餐后 2ｈ血清葡萄糖 (ＦＢＧ、Ｐ2ｈＢＧ )、糖化血红蛋白 (ＨＢＡ1Ｃ )。…     

大鼠脑内白细胞介素-1Ⅰ型受体在致痫活动中的表达变化

为了探讨白细胞介素 -1I型受体 ( IL-1RI)在癫痫发病中的作用 ,本实验采用免疫组织化学方法观察了致痫大鼠行为改变与脑内 IL-1RI表达变化。结果发现 ,侧脑室注射白细胞介素 -1β( IL-1β)后再注射阈下剂量谷氨酸钠 ,可导致动物痫样发作 ,其大脑皮质及海马锥体细胞层 IL -1RI免疫反应阳性细胞数量较对照组明显增多 ,免疫反应增强 ;如先注射白细胞介素 1受体拮抗剂 ( IL-1ra)、再注射 IL-1β和阈下剂量谷氨酸钠 ,则动物无痫样发作 ,且大脑皮质及海马锥体细胞层 IL-1RI免疫反应阳性细胞数量较注射 IL -1β和阈下剂量谷氨酸钠组减少 ,免疫反应着色减弱。结果提示 ,IL -1β有明显促进谷氨酸钠致痫的作用 ,IL-1RI可能参与致痫过程 ,IL-1ra具有抗痫效应。     

Plasma Levels of Procalcitonin and Interleukin-6 in Acute Myocardial Infarction

Estimation of cardiac morbidity in patients after major surgery is a difficult problem. In addition, infectious complications seriously decrease potential beneficial outcome after cardiovascular surgery. The present study assessed the use of a newer marker of the inflammatory response, procalcitonin, in the field of myocardial infarction, in conjunction with measurements of interleukin-6. Forty-four consecutive cases with acute myocardial infarction were included in the study 4 ± 1.3 h after the onset of symptoms. Plasma levels of procalcitonin and interleukin-6 were obtained at admission, and after 3, 6, 12, 18, 24 and 48 h, using commercially available test kits. The range of levels of interleukin-6 and procalcitonin was about normal at admission. Interleukin-6 levels increased significantly following myocardial infarction, whereas procalcitonin were essentially unchanged, i.e. remained close to the normal level threshold of 0.5 ng/ml; only minor variability occurred with a mean peak level of procalcitonin of 1 ± 0.4 ng/ml. Data demonstrate that, in contrast to the acute phase reactant interleukin-6, plasma levels procalcitonin are not significantly elevated during uncomplicated acute myocardial infarction. This observation may support the role of procalcitonin measurements in the differential diagnosis of infectious and cardiovascular complications after major surgery.     

ST段抬高性AMI患者血浆高迁移率族蛋白B1浓度的变化

目的:揭示ST段抬高性急性心肌梗死(STEAMI)患者血浆高迁移率族蛋白B1浓度的变化,探讨其临床意义。方法:收集STEAMI患者110例、健康体检者50例(作为对照组)。对照组静脉血体检时获得。STEAMI患者静脉血在入院时、入院后第1、2、3、5和7d获得。ELISA测定血浆高迁移率族蛋白B1浓度。结果:STEAMI患者住院期间主要不良心脏事件发生30例(27.3%)。STEAMI患者血浆高迁移率族蛋白B1浓度显著升高,1d内到达高峰,后逐渐下降,均显著地高于对照组(P<0.01)。在各个时间点,住院期间主要不良心脏事件发生患者血浆高迁移率族蛋白B1浓度均显著高于住院期间主要不良心脏事件不发生患者(P<0.05)。ROC曲线显示血浆高迁移率族蛋白B1浓度预测住院期间主要不良心脏事件发生有显著意义(曲线下面积=0.836,95%CI=0.776～0.873,P<0.01),且判定入院时血浆高迁移率族蛋白B1浓度>13.6 ng/ml,对预测住院期间主要不良心脏事件发生有80.0%的灵敏度和75.0%的特异度。结论:STEAMI患者血浆高迁移率族蛋白B1浓度显著升高,临床检测这个指标有助于早期判断STEAMI患者住院期间主要不良心脏事件的发生。     

女性急性心肌梗死的临床流行病学研究

目的　探讨女性急性心肌梗死 (AMI)临床流行病学特点 .方法　分析了 36 6例AMI者有关资料 ,其中男性组 2 0 0例 ,女性组 16 6例 ,按 <4 5岁、4 5～ 5 5岁、>5 5岁分 3个年龄段 ,分析内容包括 :①既往病史 ;②梗死部位 ;③血糖、血脂 ;④并发症发生率及住院病死率 ;⑤静脉溶栓治疗效果 .结果　①女性组糖尿病和高脂血症病史显著高于男性组 (p<0 .0 5 ,p<0 .0 1) ;②女性组血糖、血脂均显著高于男性组 (p <0 .0 1) ;③女性组心源性休克、心力衰竭、猝死的发生率及住院病死率均高于男性组 (p <0 .0 5 ) ;④静脉溶栓治疗中 ,男性组溶栓再通率高于女性组 (p <0 .0 1) .结论　糖尿病、高脂血症是女性AMI的危险因素 ,绝经后女性AMI发病率增高 ,并发症发生率及住院病死率均高于男性 ,静脉溶栓治疗效果较差 ,女性AMI患者近期预后差     

Interleukin-1, Interleukin-1 Receptors and Interleukin-1 Receptor Antagonist

IL-1 (IL-1α or IL-1β) is the prototypic “multifunctional” cytokine. Unlike the lymphocyte and colony stimulating growth factors, IL-1 affects nearly every cell type, and often in concert with other cytokines or small mediator molecules. Although some lymphocyte and colony stimulating growth factors may be therapeutically useful, IL-1 is a highly inflammatory cytokine and the margin between clinical benefit and unacceptable toxicity in humans is exceedingly narrow. In contrast, agents that reduce the production and/or activity of IL-1 are likely to have an impact on clinical medicine. In support of this concept, there is growing evidence that the production and activity of IL-1, particularly IL-1β, are tightly regulated events as if nature has placed specific “road blocks” to reduce the response to IL-1 during disease. In addition to controlling gene expression, synthesis and secretion, this regulation extends to surface receptors, soluble receptors and a receptor antagonist. Investigators have studied how production of the different members of the IL-1 family is controlled, the various biological activities of IL-1, the distinct and various functions of the IL-1 receptor (IL-1R) family and the complexity of intracellular signaling. Mice deficient in IL-1β, IL-1β converting enzyme (ICE) and IL-1R type I have also been studied. Humans have been injected with IL-1 (either IL-1α or IL-1β) for enhancing bone marrow recovery and for cancer treatment. The IL-1 specific receptor antagonist (IL-IRa) has also been tested in clinical trials.     

生化标志物的检测对判定急性心肌梗死溶栓后冠脉再通的临床价值

目的研究检测生化标志物血清肌红蛋白（MYO）、肌钙蛋白I（cTnI）、肌酸激酶同工酶（CK—MB）和C-反应蛋白（CRP）对急性心肌梗死溶栓冠脉再通的早期诊断价值。方法MYO、cTnI、CK—MB使用酶联免疫分析法、CRP使用激光散射比浊法测定127例急性心肌梗死患者溶栓治疗前后MYO、cTnI、CK-MB和CRP浓度和时间的变化,分析急性心肌梗死患者溶栓再通组（83例）和溶栓未通组（44例）上述指标的连续、动态演变。结果急性心肌梗死溶栓再通组MYO、cTnI、CK—MB和CRP达到峰值浓度的时间较未通组明显提前（P〈0．01）。其中MYO较cTnI、CK-MB和CRP峰值时间出现更早,分别为（6．1±2．4）h、（13．8±3．5）h、（14．4±3．8）h和（25．2±5．7）h（P〈0．01）;再通组MYO和CRP峰值浓度明显高于未通组（P〈0．01）;MYO、cTnI、CK—MB和CRP对判断冠脉再通的敏感性、特异性、预测值差异无统计学意义（P〉0．05）。结论血清MYO、cTnI、CK-MB和CRP可以较好地预测急性心肌梗死患者溶栓再通,其中MYO较cTnI、CK—MB和CRP能更早期判断冠状动脉是否再灌注;CRP对溶栓后冠脉再通的判断也有积极的参考意义。     

血浆内皮素—1和肿瘤坏死因子与急性心肌梗塞的关系

本文对２０例急性心肌梗塞（ＡＭＩ）患者检测了血浆内皮素－１（ＥＴ－１）和肿瘤坏死因子（ＴＮＦ）的水平，结果表明，ＡＭＩ组的ＥＴ－１、ＴＮＦ均较正常对照明显升高（Ｐ〈０．００１），且二者与肌酸磷酸激酶的ＭＢ同功酶（ＰＣＫ－ＭＢ）均呈正相关（ｒ＝０．０６９８４，Ｐ〈０．００１；ｒ＝０．６０５３，Ｐ〈０．０１）。研究结果说明ＥＴ－１和ＴＮＦ参与了ＡＭＩ的病理损伤过程。     

AMI患者血清ALD、Cor RIA及其临床意义

目的:探讨急性心肌梗死(AMI)患者血清醛固酮(ALD)和皮质醇(Cor)水平的变化及其临床意义.方法:采用放射免疫分析测定了58例急性心肌梗死(AMI)和30例正常对照组的血清ALD和Cor水平,进行对照统计分析.结果:AMI组血清ALD和Cor水平显著高于对照组(193.6±50.1ng/L vs 83.2±34.4ng/L, t=10.81, P＜0.01;207.0±80.2nmol/L vs 105.5±49.1 nmol/L, t=6.332,P＜0.01),且两者成显著正相关(r=0.884, P＜0.01).合并心功能不全组血清ALD和Cor均显著高于无心功能不全组(t=6.141, P＜0.01;t=6.134, P＜0.01 ),住院死亡组血清ALD和Cor也显著高于转出院组(t=5.063, P＜0.01; t=6.601, P＜0.01 ).结论:AMI患者血清ALD和Cor水平显著升高,合并心力衰竭组和住院期间死亡组升高更明显.     

瑞替普酶静脉溶栓治疗急性心肌梗死的疗效观察

目的观察瑞替普酶静脉溶栓治疗急性心肌梗死的疗效和安全性。方法30例患者均符合入选和不入选标准,予以瑞替普酶静脉溶栓治疗,观察血管再通的临床指标及不良反应。结果根据冠脉再通标准判断,30例患者血管再通构成比为76.7%,出血发生率为0.67%。结论急性心肌梗死患者选用瑞替普酶静脉溶栓是一种安全、有效的治疗方法。     

Potential Influence of Interleukin-1 Receptor Antagonist Gene Polymorphism on Knee Osteoarthritis Risk

Objectives: Genes encoding for cytokines have been associated with susceptibility for joint osteoarthritis (OA) and interleukin (IL)-1 gene is supposed to be involved in the cartilage destruction process. In this regard, interleukin-1 receptor antagonist (IL-1RA) competing with IL-1 for binding to its receptor may act as an inhibitor of cartilage breakdown. We assessed the association of primary knee OA with IL-1RA region as a putative factor of susceptibility to knee OA in Egyptian patients. Design and methods: Eighty patients with primary knee OA and 40 aged-matched healthy controls were included into the study. DNA samples were used to study genotypes of IL-1RN gene by polymerase chain reaction (PCR) in both groups. Results: An increased frequency of the IL-1RN*1 and IL-1RN*2 alleles was found in OA patients relative to controls (60.5% vs. 39.5%, P = 0.039, 85.4% vs. 14.6%, P = 0.002, respectively) however, only the carriage rate of IL-1RN*2 allele was found to be significant when OA patients were compared to the controls. Significant higher frequencies of IL-1RN*1/*2 and IL-1RN*2/*2 genotypes in OA patients were observed as compared with controls. Both visual analogue scale (VAS) and radiographic score revealed significant correlation with both the allelic frequency and the carriage rate of IL-1RN*2 allele. Moreover, absolute frequency of IL-1RN*1/*2 genotype OA patients revealed severe VAS and high radiographic score. Conclusion: These results suggest that IL-1RN*2 allele represent a significant factor influencing the severity and course of knee OA; thereby supporting the potential role of IL-1 in the pathogenesis of this disease.     

Influenza Virus Infection and Risk of Acute Myocardial Infarction

Increasing evidences have shown that pathogens might promote atherosclerosis and trigger acute myocardial infarction (AMI). But the conclusions from various studies on the correlation between previous influenza virus (IV) infection and AMI were inconsistent. We conducted a case-control study to assess the association of previous IV infection and AMI. Questionnaire survey was conducted to collect information about demographic characteristics and heart disease risk factors. Fasting blood sample was obtained to measure IgG antibodies to influenza virus A(IV-A), influenza virus B(IV-B), cytomegalovirus (CMV), herpes simplex virus type-1 (HSV-1) and type-2 (HSV-2), adenovirus (ADV), rubella virus (RV) and Chlamydia pneumoniae (CP) and measure the level of some biochemistry markers. Compared to controls, cases were more likely to have positive IgG antibodies to IV-A and IV-B (IV-A: OR, 3.3; 95%CI, 1.5 to 7.4; IV-B: OR, 17.2; 95%CI, 7.7 to 38.0). After adjustment for potential confounding variables, the risk of AMI was still associated with the presence of IgG antibodies to IV-A (adjusted OR, 7.5; 95%CI, 1.3 to 43.0) and IV-B (adjusted OR, 27.3; 95%CI, 6.6 to 113.8). The study supported the hypothesis that previous IV infection took part in the development of atherosclerosis and trigger the occurrence of AMI.